Fate Therapeutics Inc (FATE)
4.08
+0.13
(+3.29%)
USD |
NASDAQ |
May 01, 16:00
4.08
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Revenue (Quarterly): 1.676M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.676M |
| September 30, 2023 | 1.944M |
| June 30, 2023 | 0.933M |
| March 31, 2023 | 58.98M |
| December 31, 2022 | 44.36M |
| September 30, 2022 | 14.98M |
| June 30, 2022 | 18.55M |
| March 31, 2022 | 18.41M |
| December 31, 2021 | 17.07M |
| September 30, 2021 | 14.22M |
| June 30, 2021 | 13.41M |
| March 31, 2021 | 11.14M |
| December 31, 2020 | 15.90M |
| September 30, 2020 | 7.558M |
| June 30, 2020 | 5.465M |
| March 31, 2020 | 2.515M |
| December 31, 2019 | 2.802M |
| September 30, 2019 | 2.429M |
| June 30, 2019 | 2.817M |
| March 31, 2019 | 2.632M |
| December 31, 2018 | 1.661M |
| September 30, 2018 | 1.026M |
| June 30, 2018 | 1.027M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.026M |
| December 31, 2017 | 1.027M |
| September 30, 2017 | 1.026M |
| June 30, 2017 | 1.026M |
| March 31, 2017 | 1.027M |
| December 31, 2016 | 1.027M |
| September 30, 2016 | 1.026M |
| June 30, 2016 | 1.027M |
| March 31, 2016 | 1.322M |
| December 31, 2015 | 1.076M |
| September 30, 2015 | 1.026M |
| June 30, 2015 | 0.329M |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | 0.209M |
| June 30, 2013 | 0.29M |
| March 31, 2013 | 0.472M |
| December 31, 2012 | 0.643M |
| September 30, 2012 | 0.528M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.933M
Minimum
Jun 2023
58.98M
Maximum
Mar 2023
13.43M
Average
11.14M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 115.08M |
| Regeneron Pharmaceuticals Inc | 3.434B |
| Sarepta Therapeutics Inc | 396.78M |
| ADMA Biologics Inc | 73.90M |
| Ocular Therapeutix Inc | 14.80M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -44.12M |
| Total Expenses (Quarterly) | 49.75M |
| EPS Diluted (Quarterly) | -0.45 |
| Enterprise Value | 76.82M |
| Profit Margin (Quarterly) | -2.63K% |
| Earnings Yield | -40.20% |
| Normalized Earnings Yield | -40.20 |